Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 Fourth Quarter & Full Year 2020 Earnings February 4, 2021
Fourth Quarter & Full Year 2020 Earnings
February 4, 20212 IDEX Proprietary & Confidential 2Agenda
IDEX Business Overview
•Orders & End Market Update
•Q4 & Full Year Performance
Q&A3 IDEX Proprietary & Confidential 3Replay Information
•Dial toll– free: 877.660.6853
•International: 201.612.7415
•Conference ID: #13712088
•Log on to: www.idexcorp.com4 IDEX Proprietary & Confidential 4Cautionary Statement
Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures
This presentation and discussion will include forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. These statements may relate to, among other things, the anticipated effects of the coronavirus pandemic, including w ithrespect to the
Company’s revenues, facility closures and access to capital, capital expenditures, acquisitions, cost reductions, cash flow, cash requirements, revenues,
earnings, market conditions, global economies, plant and equipment capacity and operating improvements, and are indicated by wor ds or phrases such as
“anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “t he company believes,” “the company
intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause act ualresults to differ materially
from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the fol lowing: the duration of the
coronavirus pandemic and the effects of the coronavirus on our ability to operate our business and facilities, on our customers and on the U.S. and global
economy generally; economic and political consequences resulting from terrorist attacks and wars; levels of industrial activi ty and economic conditions in
the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spendin g in certain industries – all of
which could have a material impact on order rates and IDEX’s results, particularly in light of the low levels of order backlogs it typically maintains; its ability
to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dol larto other currencies and its
impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates ; interest rates; capacity
utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as
litigation and environmental matters. Additional factors that could cause actual results to differ materially from those refl ected in the forward- looking
statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the company’s most recent annual report on Form
Preview truncated — download the full document for the complete content.
investor_presentation
15 Pages
investor_presentation
31 Pages
International Personal Finance
Teva Pharmaceutical Industries Investor Presentation — March 2021
investor_presentationinvestor_presentation
18 Pages
Teva Pharmaceutical Industries